Browse VAPA

Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type IV membrane protein Cell membrane Single-pass type IV membrane protein Cell junction, tight junction Nucleus membrane Note=Present in the plasma membrane and in intracellular vesicles, together with SNARE proteins. May also associate with the cytoskeleton. Colocalizes with OCLN at the tight junction in polarized epithelial cells.
Domain PF00635 MSP (Major sperm protein) domain
Function

Binds to OSBPL3, which mediates recruitment of VAPA to plasma membrane sites (PubMed:25447204). The ORP3-VAPA complex stimulates RRAS signaling which in turn attenuates integrin beta-1 (ITGB1) activation at the cell surface (PubMed:25447204). With OSBPL3, may regulate ER morphology (PubMed:16143324). May play a role in vesicle trafficking (PubMed:11511104, PubMed:19289470).

> Gene Ontology
 
Biological Process GO:0006643 membrane lipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006900 membrane budding
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0016050 vesicle organization
GO:0019048 modulation by virus of host morphology or physiology
GO:0019054 modulation by virus of host process
GO:0019058 viral life cycle
GO:0019076 viral release from host cell
GO:0019079 viral genome replication
GO:0030148 sphingolipid biosynthetic process
GO:0035821 modification of morphology or physiology of other organism
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044003 modification by symbiont of host morphology or physiology
GO:0044068 modulation by symbiont of host cellular process
GO:0044788 modulation by host of viral process
GO:0044789 modulation by host of viral release from host cell
GO:0044791 positive regulation by host of viral release from host cell
GO:0044793 negative regulation by host of viral process
GO:0044794 positive regulation by host of viral process
GO:0044827 modulation by host of viral genome replication
GO:0044828 negative regulation by host of viral genome replication
GO:0044829 positive regulation by host of viral genome replication
GO:0045069 regulation of viral genome replication
GO:0045070 positive regulation of viral genome replication
GO:0045071 negative regulation of viral genome replication
GO:0046467 membrane lipid biosynthetic process
GO:0048193 Golgi vesicle transport
GO:0048524 positive regulation of viral process
GO:0048525 negative regulation of viral process
GO:0050792 regulation of viral process
GO:0051701 interaction with host
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0061025 membrane fusion
GO:0070972 protein localization to endoplasmic reticulum
GO:0090114 COPII-coated vesicle budding
GO:1902186 regulation of viral release from host cell
GO:1902188 positive regulation of viral release from host cell
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0033149 FFAT motif binding
GO:0045296 cadherin binding
GO:0046982 protein heterodimerization activity
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005635 nuclear envelope
GO:0005913 cell-cell adherens junction
GO:0005923 bicellular tight junction
GO:0031965 nuclear membrane
GO:0043296 apical junction complex
GO:0070160 occluding junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-1660661: Sphingolipid de novo biosynthesis
R-HSA-428157: Sphingolipid metabolism
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VAPA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VAPA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.62; FDR: 0.012 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VAPA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0820.67
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1490.943
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0290.984
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0750.803
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2250.912
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1160.965
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1250.773
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0140.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2520.908
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2330.908
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0280.993
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1310.0798
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VAPA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VAPA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VAPA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VAPA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VAPA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VAPA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VAPA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVAPA
NameVAMP (vesicle-associated membrane protein)-associated protein A, 33kDa
Aliases hVAP-33; VAP-A; VAMP (vesicle-associated membrane protein)-associated protein A (33kD); VAP-33; VAP33; 33 kD ......
Chromosomal Location18p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VAPA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.